260 related articles for article (PubMed ID: 29209044)
1. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines.
Maura F; Petljak M; Lionetti M; Cifola I; Liang W; Pinatel E; Alexandrov LB; Fullam A; Martincorena I; Dawson KJ; Angelopoulos N; Samur MK; Szalat R; Zamora J; Tarpey P; Davies H; Corradini P; Anderson KC; Minvielle S; Neri A; Avet-Loiseau H; Keats J; Campbell PJ; Munshi NC; Bolli N
Leukemia; 2018 Apr; 32(4):1044-1048. PubMed ID: 29209044
[No Abstract] [Full Text] [Related]
2. N- and K-ras oncogenes in plasma cell dyscrasias.
Corradini P; Ladetto M; Inghirami G; Boccadoro M; Pileri A
Leuk Lymphoma; 1994 Sep; 15(1-2):17-20. PubMed ID: 7858496
[TBL] [Abstract][Full Text] [Related]
3. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias.
Corradini P; Ladetto M; Voena C; Palumbo A; Inghirami G; Knowles DM; Boccadoro M; Pileri A
Blood; 1993 May; 81(10):2708-13. PubMed ID: 8490179
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias.
Corradini P; Inghirami G; Astolfi M; Ladetto M; Voena C; Ballerini P; Gu W; Nilsson K; Knowles DM; Boccadoro M
Leukemia; 1994 May; 8(5):758-67. PubMed ID: 8182933
[TBL] [Abstract][Full Text] [Related]
5. Lack of BCL10 mutations in multiple myeloma and plasma cell leukemia.
Shih LY; Fu JF; Shurtleff SA; Morris SW; Downing JR
Genes Chromosomes Cancer; 2001 Apr; 30(4):402-6. PubMed ID: 11241793
[TBL] [Abstract][Full Text] [Related]
6. Compendium of FAM46C gene mutations in plasma cell dyscrasias.
Barbieri M; Manzoni M; Fabris S; Ciceri G; Todoerti K; Simeon V; Musto P; Cortelezzi A; Baldini L; Neri A; Lionetti M
Br J Haematol; 2016 Aug; 174(4):642-5. PubMed ID: 26456599
[No Abstract] [Full Text] [Related]
7. Occurrence and type of chromosomal abnormalities in consecutive malignant monoclonal gammopathies: correlation with survival.
Lisse IM; Drivsholm A; Christoffersen P
Cancer Genet Cytogenet; 1988 Oct; 35(1):27-36. PubMed ID: 3180005
[TBL] [Abstract][Full Text] [Related]
8. In-vivo detectable antibodies directed against the oncofetal antigen/immature laminin receptor can recognize and control myeloma cells--clinical implications.
Siegel S; Friedrichs B; Budde AK; Barsoum A; Coggin J; Tiemann M; Kabelitz D; Zeis M
Leukemia; 2008 Nov; 22(11):2115-8. PubMed ID: 18449203
[No Abstract] [Full Text] [Related]
9. CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q.
Mitsiades CS
Haematologica; 2005 Apr; 90(4):436-7. PubMed ID: 15820931
[No Abstract] [Full Text] [Related]
10. Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.
Lionetti M; Barbieri M; Todoerti K; Agnelli L; Marzorati S; Fabris S; Ciceri G; Galletti S; Milesi G; Manzoni M; Mazzoni M; Greco A; Tonon G; Musto P; Baldini L; Neri A
Oncotarget; 2015 Sep; 6(27):24205-17. PubMed ID: 26090869
[TBL] [Abstract][Full Text] [Related]
11. A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias.
Lionetti M; Barbieri M; Todoerti K; Agnelli L; Fabris S; Tonon G; Segalla S; Cifola I; Pinatel E; Tassone P; Musto P; Baldini L; Neri A
Oncotarget; 2015 Sep; 6(28):26129-41. PubMed ID: 26305418
[TBL] [Abstract][Full Text] [Related]
12. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors.
Avet-Loiseau H; Gerson F; Magrangeas F; Minvielle S; Harousseau JL; Bataille R;
Blood; 2001 Nov; 98(10):3082-6. PubMed ID: 11698294
[TBL] [Abstract][Full Text] [Related]
13. Mutational processes contributing to the development of multiple myeloma.
Hoang PH; Cornish AJ; Dobbins SE; Kaiser M; Houlston RS
Blood Cancer J; 2019 Aug; 9(8):60. PubMed ID: 31387987
[TBL] [Abstract][Full Text] [Related]
14. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.
Rasillo A; Tabernero MD; Sánchez ML; Pérez de Andrés M; Martín Ayuso M; Hernández J; Moro MJ; Fernández-Calvo J; Sayagués JM; Bortoluci A; San Miguel JF; Orfao A
Cancer; 2003 Feb; 97(3):601-9. PubMed ID: 12548602
[TBL] [Abstract][Full Text] [Related]
15. Mutational landscape reflects the biological continuum of plasma cell dyscrasias.
Rossi A; Voigtlaender M; Janjetovic S; Thiele B; Alawi M; März M; Brandt A; Hansen T; Radloff J; Schön G; Hegenbart U; Schönland S; Langer C; Bokemeyer C; Binder M
Blood Cancer J; 2017 Feb; 7(2):e537. PubMed ID: 28234344
[TBL] [Abstract][Full Text] [Related]
16. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment.
Pérez-Andrés M; Almeida J; Martín-Ayuso M; Moro MJ; Martín-Nuñez G; Galende J; Borrego D; Rodríguez MJ; Ortega F; Hernandez J; Moreno I; Domínguez M; Mateo G; San Miguel JF; Orfao A; ;
Leukemia; 2005 Mar; 19(3):449-55. PubMed ID: 15674420
[TBL] [Abstract][Full Text] [Related]
17. Molecular origins of APOBEC-associated mutations in cancer.
Petljak M; Maciejowski J
DNA Repair (Amst); 2020 Oct; 94():102905. PubMed ID: 32818816
[TBL] [Abstract][Full Text] [Related]
18. BRAF gene is not mutated in plasma cell leukemia and multiple myeloma.
Bonello L; Voena C; Ladetto M; Boccadoro M; Palestro G; Inghirami G; Chiarle R
Leukemia; 2003 Nov; 17(11):2238-40. PubMed ID: 12931219
[No Abstract] [Full Text] [Related]
19. Redefining high risk multiple myeloma with an APOBEC/Inflammation-based classifier.
Grasedieck S; Panahi A; Jarvis MC; Borzooee F; Harris RS; Larijani M; Avet-Loiseau H; Samur M; Munshi N; Song K; Rouhi A; Kuchenbauer F
Leukemia; 2024 May; 38(5):1172-1177. PubMed ID: 38461190
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of ITGA6 confers to the invasion of multiple myeloma and promotes progression to plasma cell leukaemia.
Song S; Zhang J; Su Q; Zhang W; Jiang Y; Fan G; Qian C; Li B; Zhuang W
Br J Cancer; 2021 May; 124(11):1843-1853. PubMed ID: 33785876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
